Quince Therapeutics

127 articles about Quince Therapeutics

• Cortexyme to Present at Investor Conferences in June 2021

  5/26/2021

  Cortexyme, Inc., a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021

• Cortexyme Provides Business Update and Reports First Quarter 2021 Results

  5/10/2021

  Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021

• Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

  5/4/2021

  Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event

• Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021

  3/25/2021

  Cortexyme to Present at the Stifel 3 rd Annual CNS Day on April 1, 2021

• Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021

  3/10/2021

  Cortexyme to Present at the Oppenheimer 31 st Annual Healthcare Conference on March 16, 2021 -- Presentation to be webcast on Cortexyme’s website --

• Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease

  2/16/2021

  Cortexyme, Inc., a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, received a letter from the U.S. Food and Drug Administration stating that a partial clinical hold has been placed on atuzaginstat impacting the open-label extension phase of the company’s ongoing Phase 2/3 study, the GAIN Trial.

• 

  FDA Places Partial Clinical Hold on Trial of Alzheimer's Drug Atuzaginstat

  2/16/2021

  According to a statement made by Cortexyme, the partial hold was placed on the development program for atuzaginstat after an FDA review of the trial data identified hepatic adverse events.

• Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion

  2/10/2021

  — Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality

• Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones

  1/26/2021

  — Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line data in 643 subject Alzheimer’s disease pivotal GAIN Trial on schedule to be announced in Q4 2021

• Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis

  12/4/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue the Phase 2/3 GAIN Trial of atuzaginstat (COR388) as planned to the 1-year endpoint. 

• Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease Conference

  11/5/2020

  -- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, granted by the conference’s organizers --

• Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

  9/24/2020

  Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to mode

• Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

  9/9/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14

• Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

  8/27/2020

    - New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years

• Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update

  8/17/2020

  — GAIN Trial enrollment on track to complete in Q4 2020 — GAIN Trial interim analysis on schedule to complete by year end 2020 — Clinical pipeline expansion anticipated in 2021

• Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020

  8/6/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will present at the following two investor conferences in August 2020:

• Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020

  7/29/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will participate in a fireside chat hosted by LifeSci Capital on Thursday, July 30 at 3:00 p.m. EDT

• Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases

  7/28/2020

  Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases -- Researchers presented new preclinical data on atuzaginstat and the potential impact on cardiovascular disease and AD-associated neurodegeneration in two poster presentations at AAIC 2020 -- Cortexyme also presented phase 1

• Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020

  7/22/2020

  Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association International Conference ® 2020 (AAIC ® ). The largest international meeting dedicated to advancing dementia science, AAIC will be held

• Cortexyme Announces “Atuzaginstat” Selected as First-in-Class Nonproprietary Name for COR388

  6/9/2020

  Cortexyme, Inc. announced that the International Nonproprietary Naming Committee of the World Health Organization has selected atuzaginstat as the proposed International Nonproprietary Name, or pINN, for the company’s lead product candidate COR388.